SAN FRANCISCO & SEOUL, Korea--(BUSINESS WIRE)--AmStem Corporation (Pink Sheets: AMST), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced today that the largest independent, federally regulated Institutional Review Board (IRB) in North America has approved the initial clinical study of the company’s SteMixxTM facial cream. The study is expected to begin this week at the Scottsdale Institute for Cosmetic Dermatology and will last approximately two months.
